Beijing Science Sun Pharmaceutical Co., Ltd. Share Price

Equities

300485

CNE100002110

Pharmaceuticals

End-of-day quote Shenzhen S.E. 03:30:00 07/05/2024 am IST 5-day change 1st Jan Change
8.15 CNY +1.75% Intraday chart for Beijing Science Sun Pharmaceutical Co., Ltd. +8.23% -23.04%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Take advantage of the offer
* See conditions on site

Financials

Sales 2022 735M 102M 8.49B Sales 2023 477M 66.03M 5.51B Capitalization 5.1B 707M 58.98B
Net income 2022 205M 28.4M 2.37B Net income 2023 103M 14.27M 1.19B EV / Sales 2022 6.33 x
Net cash position 2022 1.12B 155M 12.97B Net cash position 2023 1.17B 163M 13.57B EV / Sales 2023 8.24 x
P/E ratio 2022
27.9 x
P/E ratio 2023
50.4 x
Employees -
Yield 2022
0.72%
Yield 2023
0.21%
Free-Float 41.18%
More Fundamentals * Assessed data
Dynamic Chart
Beijing Science Sun Pharmaceutical Co., Ltd. agreed to acquire 5.6664% stake in Suzhou Inhal Pharma Co., Ltd. from Ningbo Menovo Ruihe Equity Investment Partnership for CNY 10 million. CI
Beijing Science Sun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Beijing Science Sun Pharmaceutical Co., Ltd. Proposes Final Cash Dividend (Tax Included) for the Year 2023 CI
Beijing Science Sun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Beijing Science Sun Pharmaceutical Co., Ltd. Announces Executive Changes CI
Beijing Science Sun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Beijing Science Sun Pharmaceutical Co., Ltd.(XSEC:300485) added to S&P Global BMI Index CI
Beijing Science Sun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Beijing Science Sun Pharmaceutical Co., Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date of 23 May 2023 CI
Beijing Science Sun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Beijing Science Sun Pharmaceutical Co., Ltd. Approves Final Dividend for 2022 CI
Beijing Science Sun Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2022 CI
Beijing Science Sun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Lin Xuehua completed the acquisition of a 45% stake in Beijing Zhongrun Weiye Investment Co., Ltd. from Beijing Science Sun Pharmaceutical Co., Ltd. for CNY 6.6 million. CI
Science Sun Pharma Passes Inspection of Premises MT
More news
1 day+1.75%
1 week+8.23%
Current month+6.54%
1 month-4.34%
3 months+13.04%
6 months-28.51%
Current year-23.04%
More quotes
1 week
7.72
Extreme 7.72
8.22
1 month
6.90
Extreme 6.9
8.48
Current year
6.53
Extreme 6.53
10.74
1 year
6.53
Extreme 6.53
12.27
3 years
6.53
Extreme 6.53
18.75
5 years
6.53
Extreme 6.53
28.08
10 years
6.53
Extreme 6.53
44.20
More quotes
Managers TitleAgeSince
Chief Executive Officer 60 05/01/05
Chief Administrative Officer 45 28/21/28
Chief Tech/Sci/R&D Officer 49 01/01/01
Members of the board TitleAgeSince
Director/Board Member 51 26/01
Director/Board Member 46 01/99/01
Chief Executive Officer 60 05/01/05
More insiders
Date Price Change Volume
07/24/07 8.15 +1.75% 6 081 968
06/24/06 8.01 +4.71% 6,755,220
30/24/30 7.65 +1.59% 4,639,700

End-of-day quote Shenzhen S.E., May 07, 2024

More quotes
Beijing Science Sun Pharmaceutical Co., LTD. is a China-based company principally engaged in research, manufacture and sales of biological and biochemical pharmaceuticals. The Company' products can be divided into cardiovascular series, immune regulation series, nervous system series and other natural or biotech pharmaceuticals. Its products include small capacity injection and freeze-dried powder injection.
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300485 Stock
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW